PUBLISHER: Acute Market Reports | PRODUCT CODE: 1180651
PUBLISHER: Acute Market Reports | PRODUCT CODE: 1180651
Human Chorionic Gonadotropin Market - Growth, Future Prospects and Competitive Analysis, 2022 - 2030
Global Human Chorionic Gonadotropin Market is having an exponential growth rate of 7.5% from 2022 to 2030.
Fertility patterns worldwide have changed dramatically and a rise in infertility rates have been observed since the last two decades. Even though newer assisted techniques such as in-vitro fertilization have been well developed, still fertility drugs are the first choice for treatment of infertility issues. Even in the fertility drugs category, hormonal products are preferred the most. Since the human body is governed by hormones, infertility is considered to be caused due to the abnormal play of the hormones.
Human chorionic gonadotropin (HCG) is available in two forms. One is a powder derived from the urine of pregnant women which needs to be dissolved in sterile water, loaded into a syringe, and injected into a muscle. Ovidrel is another more expensive but more convenient product produced by recombinant technology, pre-packaged into a syringe for injection with a short needle. HCG is used in some patients who are usually receiving other fertility drugs in order to trigger ovulation. The eggs are released from their follicles about 40 hours after the HCG injection. Artificial insemination will usually be scheduled for 36-44 hours after the HCG injection when a single insemination is planned or at approximately 24 and 48 hours after the HCG injection when two inseminations are to be done.
Two main regimens of gonadotropin ovarian stimulation are used, namely step-up and the step-down protocols. The choice of gonadotropin preparation and treatment regimen depends on the underlying ovarian dysfunction. Strict monitoring of gonadotropin treatment with implementation of strict cancellation criteria are recommended to minimize the risks of ovarian hyperstimulation and multiple pregnancy.
Oligospermia supported the demand for HCG drugs in the market
For the purpose of this study, the global human chorionic gonadotropin market is represented by key therapeutic areas such as female infertility treatment, oligospermia, cryptorchidism and others. Several factors such as growing incidence of infertility in women, contributed by increased maternity age, lifestyle effects and others, hormonal dysfunctions in men and growing incidence of oligospermia are the key factors that have supported the demand for HCG drugs in the market.
Recombinant HCG is Key driving factor
For the purpose of this report, the technology segment of the global human chorionic gonadotropin market has been segmented into natural source extract and recombinant DNA technology. Urine-derived HCG has been a chief treatment source for various hormonal conditions. However in view of purity-related issues, HCG manufacturing through recombinant production technology. Equal efficacy or recombinant HCG along with added safety as against natural source HCG are the key driving factors that lead to higher demand for recombinant HCG in the global market.
Asia-Pacific is expected to be the most potential regional market
North America is expected to be the largest and most potential regional market for human chorionic gonadotropin. North America constitutes regional markets of U.S. and Canada, the rising incidence of infertility cases, lifestyle effects, and others, hormonal dysfunctions in men and women are the major driver for the growth of the global human chorionic gonadotropin market. Asia-Pacific is expected to be the most potential regional market for human chorionic gonadotropin market by 2030. Over the next six years, the growth of the market in the Asia-Pacific region is likely to be centered in Japan, South Korea, China, and India. Numerous factors such as developing economical landscape, increasing disposable incomes, growing public awareness related to infertility therapy, and increasing government support through providing favorable policies are the major factors expected to assist the growth of Asia-Pacific market.
Market Players
The leading key players in human chorionic gonadotropin market are EMD Serono, Inc., Ferring B.V., Merck & Co., Inc., Bristol Myers Squibb Company and Fresenius Kabi USA, LLC.
Historical & Forecast Period
This study report represents analysis of each segment from 2020 to 2030 considering 2021 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2022 to 2030.
The current report comprises of quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends and technological analysis, case studies, strategic conclusions and recommendations and other key market insights.
Research Methodology
The complete research study was conducted in three phases, namely: secondary research, primary research, and expert panel review. key data point that enables the estimation of Human Chorionic Gonadotropin market are as follows:
Research and development budgets of manufacturers and government spending
Revenues of key companies in the market segment
Number of end users and consumption volume, price and value.
Geographical revenues generate by countries considered in the report:
Micro and macro environment factors that are currently influencing the Human Chorionic Gonadotropin market and their expected impact during the forecast period.
Market forecast was performed through proprietary software that analyzes various qualitative and quantitative factors. Growth rate and CAGR were estimated through intensive secondary and primary research. Data triangulation across various data points provides accuracy across various analyzed market segments in the report. Application of both top down and bottom-up approach for validation of market estimation assures logical, methodical and mathematical consistency of the quantitative data.
Market Segmentation
Treatment
Female Infertility Treatment
Oligospermia Treatment
Cryptorchidism Treatment
Others
Technology
Natural Source Extraction
Recombinant DNA Technology
Region Segment (2020-2030; US$ Million)
North America
U.S.
Canada
Rest of North America
UK and European Union
UK
Germany
Spain
Italy
France
Rest of Europe
Asia Pacific
China
Japan
India
Australia
South Korea
Rest of Asia Pacific
Latin America
Brazil
Mexico
Rest of Latin America
Middle East and Africa
GCC
Africa
Rest of Middle East and Africa
Global Impact of COVID-19 Segment (2020-2021; US$ Million )
Pre COVID-19 situation
Post COVID-19 situation
Key questions answered in this report:
What are the key micro and macro environmental factors that are impacting the growth of Human Chorionic Gonadotropin market?
What are the key investment pockets with respect to product segments and geographies currently and during the forecast period?
Estimated forecast and market projections up to 2030.
Which segment accounts for the fastest CAGR during the forecast period?
Which market segment holds a larger market share and why?
Are low and middle-income economies investing in the Human Chorionic Gonadotropin market?
Which is the largest regional market for Human Chorionic Gonadotropin market?
What are the market trends and dynamics in emerging markets such as Asia Pacific, Latin America, and Middle East & Africa?
Which are the key trends driving Human Chorionic Gonadotropin market growth?
Who are the key competitors and what are their key strategies to enhance their market presence in the Human Chorionic Gonadotropin market worldwide?
Table of Contents
1. Preface
- 1.1. Report Description
- 1.1.1. Purpose of the Report
- 1.1.2. Target Audience
- 1.1.3. Key Offerings
- 1.2. Market Segmentation
- 1.3. Research Methodology
- 1.3.1. Phase I - Secondary Research
- 1.3.2. Phase II - Primary Research
- 1.3.3. Phase III - Expert Panel Review
- 1.3.4. Assumptions
- 1.3.5. Approach Adopted
2. Executive Summary
- 2.1. Market Snapshot: Global Human Chorionic Gonadotropin Market
- 2.2. Global Human Chorionic Gonadotropin Market, By Treatment, 2021 (US$ Million)
- 2.3. Global Human Chorionic Gonadotropin Market, By Technology, 2021 (US$ Million)
- 2.4. Global Human Chorionic Gonadotropin Market, By Geography, 2021 (US$ Million)
- 2.5. Attractive Investment Proposition by Geography, 2021
3. Human Chorionic Gonadotropin Market: Competitive Analysis
- 3.1. Market Positioning of Key Human Chorionic Gonadotropin Market Vendors
- 3.2. Strategies Adopted by Human Chorionic Gonadotropin Market Vendors
- 3.3. Key Industry Strategies
- 3.4. Tier Analysis 2021 Versus 2030
4. Human Chorionic Gonadotropin Market: Macro Analysis & Market Dynamics
- 4.1. Introduction
- 4.2. Global Human Chorionic Gonadotropin Market Value, 2020 - 2030, (US$ Million)
- 4.3. Market Dynamics
- 4.3.1. Market Drivers
- 4.3.2. Market Restraints
- 4.3.3. Key Challenges
- 4.3.4. Key Opportunities
- 4.4. Impact Analysis of Drivers and Restraints
- 4.5. See-Saw Analysis
5. Human Chorionic Gonadotropin Market: By Treatment, 2020-2030, USD (Million)
- 5.1. Market Overview
- 5.2. Growth & Revenue Analysis: 2021 Versus 2030
- 5.3. Market Segmentation
- 5.3.1. Female Infertility Treatment
- 5.3.2. Oligospermia Treatment
- 5.3.3. Cryptorchidism Treatment
- 5.3.4. Others
6. Human Chorionic Gonadotropin Market: By Technology, 2020-2030, USD (Million)
- 6.1. Market Overview
- 6.2. Growth & Revenue Analysis: 2021 Versus 2030
- 6.3. Market Segmentation
- 6.3.1. Natural Source Extraction
- 6.3.2. Recombinant DNA Technology
7. North America Human Chorionic Gonadotropin Market, 2020-2030, USD (Million)
- 7.1. Market Overview
- 7.2. Human Chorionic Gonadotropin Market: By Treatment, 2020-2030, USD (Million)
- 7.3. Human Chorionic Gonadotropin Market: By Technology, 2020-2030, USD (Million)
- 7.4.Human Chorionic Gonadotropin Market: By Region, 2020-2030, USD (Million)
- 7.4.1.North America
- 7.4.1.1. U.S.
- 7.4.1.1.1. Human Chorionic Gonadotropin Market: By Treatment, 2020-2030, USD (Million)
- 7.4.1.1.1. Human Chorionic Gonadotropin Market: By Technology, 2020-2030, USD (Million)
- 7.4.1.2. Canada
- 7.4.1.2.1. Human Chorionic Gonadotropin Market: By Treatment, 2020-2030, USD (Million)
- 7.4.1.2.1. Human Chorionic Gonadotropin Market: By Technology, 2020-2030, USD (Million)
- 7.4.1.3. Rest of North America
- 7.4.1.3.1. Human Chorionic Gonadotropin Market: By Treatment, 2020-2030, USD (Million)
- 7.4.1.3.1. Human Chorionic Gonadotropin Market: By Technology, 2020-2030, USD (Million)
- 7.4.1.1. U.S.
- 7.4.1.North America
8. UK and European Union Human Chorionic Gonadotropin Market, 2020-2030, USD (Million)
- 8.1. Market Overview
- 8.2. Human Chorionic Gonadotropin Market: By Treatment, 2020-2030, USD (Million)
- 8.3. Human Chorionic Gonadotropin Market: By Technology, 2020-2030, USD (Million)
- 8.4.Human Chorionic Gonadotropin Market: By Region, 2020-2030, USD (Million)
- 8.4.1.UK and European Union
- 8.4.1.1. UK
- 8.4.1.1.1. Human Chorionic Gonadotropin Market: By Treatment, 2020-2030, USD (Million)
- 8.4.1.1.1. Human Chorionic Gonadotropin Market: By Technology, 2020-2030, USD (Million)
- 8.4.1.2. Germany
- 8.4.1.2.1. Human Chorionic Gonadotropin Market: By Treatment, 2020-2030, USD (Million)
- 8.4.1.2.1. Human Chorionic Gonadotropin Market: By Technology, 2020-2030, USD (Million)
- 8.4.1.3. Spain
- 8.4.1.3.1. Human Chorionic Gonadotropin Market: By Treatment, 2020-2030, USD (Million)
- 8.4.1.3.1. Human Chorionic Gonadotropin Market: By Technology, 2020-2030, USD (Million)
- 8.4.1.4. Italy
- 8.4.1.4.1. Human Chorionic Gonadotropin Market: By Treatment, 2020-2030, USD (Million)
- 8.4.1.4.1. Human Chorionic Gonadotropin Market: By Technology, 2020-2030, USD (Million)
- 8.4.1.5. France
- 8.4.1.5.1. Human Chorionic Gonadotropin Market: By Treatment, 2020-2030, USD (Million)
- 8.4.1.5.1. Human Chorionic Gonadotropin Market: By Technology, 2020-2030, USD (Million)
- 8.4.1.6. Rest of Europe
- 8.4.1.6.1. Human Chorionic Gonadotropin Market: By Treatment, 2020-2030, USD (Million)
- 8.4.1.6.1. Human Chorionic Gonadotropin Market: By Technology, 2020-2030, USD (Million)
- 8.4.1.1. UK
- 8.4.1.UK and European Union
9. Asia Pacific Human Chorionic Gonadotropin Market, 2020-2030, USD (Million)
- 9.1. Market Overview
- 9.2. Human Chorionic Gonadotropin Market: By Treatment, 2020-2030, USD (Million)
- 9.3. Human Chorionic Gonadotropin Market: By Technology, 2020-2030, USD (Million)
- 9.4.Human Chorionic Gonadotropin Market: By Region, 2020-2030, USD (Million)
- 9.4.1.Asia Pacific
- 9.4.1.1. China
- 9.4.1.1.1. Human Chorionic Gonadotropin Market: By Treatment, 2020-2030, USD (Million)
- 9.4.1.1.1. Human Chorionic Gonadotropin Market: By Technology, 2020-2030, USD (Million)
- 9.4.1.2. Japan
- 9.4.1.2.1. Human Chorionic Gonadotropin Market: By Treatment, 2020-2030, USD (Million)
- 9.4.1.2.1. Human Chorionic Gonadotropin Market: By Technology, 2020-2030, USD (Million)
- 9.4.1.3. India
- 9.4.1.3.1. Human Chorionic Gonadotropin Market: By Treatment, 2020-2030, USD (Million)
- 9.4.1.3.1. Human Chorionic Gonadotropin Market: By Technology, 2020-2030, USD (Million)
- 9.4.1.4. Australia
- 9.4.1.4.1. Human Chorionic Gonadotropin Market: By Treatment, 2020-2030, USD (Million)
- 9.4.1.4.1. Human Chorionic Gonadotropin Market: By Technology, 2020-2030, USD (Million)
- 9.4.1.5. South Korea
- 9.4.1.5.1. Human Chorionic Gonadotropin Market: By Treatment, 2020-2030, USD (Million)
- 9.4.1.5.1. Human Chorionic Gonadotropin Market: By Technology, 2020-2030, USD (Million)
- 9.4.1.6. Rest of Asia Pacific
- 9.4.1.6.1. Human Chorionic Gonadotropin Market: By Treatment, 2020-2030, USD (Million)
- 9.4.1.6.1. Human Chorionic Gonadotropin Market: By Technology, 2020-2030, USD (Million)
- 9.4.1.1. China
- 9.4.1.Asia Pacific
10. Latin America Human Chorionic Gonadotropin Market, 2020-2030, USD (Million)
- 10.1. Market Overview
- 10.2. Human Chorionic Gonadotropin Market: By Treatment, 2020-2030, USD (Million)
- 10.3. Human Chorionic Gonadotropin Market: By Technology, 2020-2030, USD (Million)
- 10.4.Human Chorionic Gonadotropin Market: By Region, 2020-2030, USD (Million)
- 10.4.1.Latin America
- 10.4.1.1. Brazil
- 10.4.1.1.1. Human Chorionic Gonadotropin Market: By Treatment, 2020-2030, USD (Million)
- 10.4.1.1.1. Human Chorionic Gonadotropin Market: By Technology, 2020-2030, USD (Million)
- 10.4.1.2. Mexico
- 10.4.1.2.1. Human Chorionic Gonadotropin Market: By Treatment, 2020-2030, USD (Million)
- 10.4.1.2.1. Human Chorionic Gonadotropin Market: By Technology, 2020-2030, USD (Million)
- 10.4.1.3. Rest of Latin America
- 10.4.1.3.1. Human Chorionic Gonadotropin Market: By Treatment, 2020-2030, USD (Million)
- 10.4.1.3.1. Human Chorionic Gonadotropin Market: By Technology, 2020-2030, USD (Million)
- 10.4.1.1. Brazil
- 10.4.1.Latin America
11. Middle East and Africa Human Chorionic Gonadotropin Market, 2020-2030, USD (Million)
- 11.1. Market Overview
- 11.2. Human Chorionic Gonadotropin Market: By Treatment, 2020-2030, USD (Million)
- 11.3. Human Chorionic Gonadotropin Market: By Technology, 2020-2030, USD (Million)
- 11.4.Human Chorionic Gonadotropin Market: By Region, 2020-2030, USD (Million)
- 11.4.1.Middle East and Africa
- 11.4.1.1. GCC
- 11.4.1.1.1. Human Chorionic Gonadotropin Market: By Treatment, 2020-2030, USD (Million)
- 11.4.1.1.1. Human Chorionic Gonadotropin Market: By Technology, 2020-2030, USD (Million)
- 11.4.1.2. Africa
- 11.4.1.2.1. Human Chorionic Gonadotropin Market: By Treatment, 2020-2030, USD (Million)
- 11.4.1.2.1. Human Chorionic Gonadotropin Market: By Technology, 2020-2030, USD (Million)
- 11.4.1.3. Rest of Middle East and Africa
- 11.4.1.3.1. Human Chorionic Gonadotropin Market: By Treatment, 2020-2030, USD (Million)
- 11.4.1.3.1. Human Chorionic Gonadotropin Market: By Technology, 2020-2030, USD (Million)
- 11.4.1.1. GCC
- 11.4.1.Middle East and Africa
12. Company Profile
- 12.1. Ferring B.V.
- 12.1.1. Company Overview
- 12.1.2. Financial Performance
- 12.1.3. Product Portfolio
- 12.1.4. Strategic Initiatives
- 12.2. Bristol-Myers Squibb Company
- 12.2.1. Company Overview
- 12.2.2. Financial Performance
- 12.2.3. Product Portfolio
- 12.2.4. Strategic Initiatives
- 12.3. EMD Serono, Inc.
- 12.3.1. Company Overview
- 12.3.2. Financial Performance
- 12.3.3. Product Portfolio
- 12.3.4. Strategic Initiatives
- 12.4. Fresenius Kabi USA, LLC
- 12.4.1. Company Overview
- 12.4.2. Financial Performance
- 12.4.3. Product Portfolio
- 12.4.4. Strategic Initiatives
- 12.5. Merck & Co., Inc.
- 12.5.1. Company Overview
- 12.5.2. Financial Performance
- 12.5.3. Product Portfolio
- 12.5.4. Strategic Initiatives
List of Tables
- TABLE 1 Global Human Chorionic Gonadotropin Market By Treatment, 2020-2030, USD (Million)
- TABLE 2 Global Human Chorionic Gonadotropin Market By Technology, 2020-2030, USD (Million)
- TABLE 3 North America Human Chorionic Gonadotropin Market By Treatment, 2020-2030, USD (Million)
- TABLE 4 North America Human Chorionic Gonadotropin Market By Technology, 2020-2030, USD (Million)
- TABLE 5 U.S. Human Chorionic Gonadotropin Market By Treatment, 2020-2030, USD (Million)
- TABLE 6 U.S. Human Chorionic Gonadotropin Market By Technology, 2020-2030, USD (Million)
- TABLE 7 Canada Human Chorionic Gonadotropin Market By Treatment, 2020-2030, USD (Million)
- TABLE 8 Canada Human Chorionic Gonadotropin Market By Technology, 2020-2030, USD (Million)
- TABLE 9 Rest of North America Human Chorionic Gonadotropin Market By Treatment, 2020-2030, USD (Million)
- TABLE 10 Rest of North America Human Chorionic Gonadotropin Market By Technology, 2020-2030, USD (Million)
- TABLE 11 UK and European Union Human Chorionic Gonadotropin Market By Treatment, 2020-2030, USD (Million)
- TABLE 12 UK and European Union Human Chorionic Gonadotropin Market By Technology, 2020-2030, USD (Million)
- TABLE 13 UK Human Chorionic Gonadotropin Market By Treatment, 2020-2030, USD (Million)
- TABLE 14 UK Human Chorionic Gonadotropin Market By Technology, 2020-2030, USD (Million)
- TABLE 15 Germany Human Chorionic Gonadotropin Market By Treatment, 2020-2030, USD (Million)
- TABLE 16 Germany Human Chorionic Gonadotropin Market By Technology, 2020-2030, USD (Million)
- TABLE 17 Spain Human Chorionic Gonadotropin Market By Treatment, 2020-2030, USD (Million)
- TABLE 18 Spain Human Chorionic Gonadotropin Market By Technology, 2020-2030, USD (Million)
- TABLE 19 Italy Human Chorionic Gonadotropin Market By Treatment, 2020-2030, USD (Million)
- TABLE 20 Italy Human Chorionic Gonadotropin Market By Technology, 2020-2030, USD (Million)
- TABLE 21 France Human Chorionic Gonadotropin Market By Treatment, 2020-2030, USD (Million)
- TABLE 22 France Human Chorionic Gonadotropin Market By Technology, 2020-2030, USD (Million)
- TABLE 23 Rest of Europe Human Chorionic Gonadotropin Market By Treatment, 2020-2030, USD (Million)
- TABLE 24 Rest of Europe Human Chorionic Gonadotropin Market By Technology, 2020-2030, USD (Million)
- TABLE 25 Asia Human Chorionic Gonadotropin Market By Treatment, 2020-2030, USD (Million)
- TABLE 26 Asia Human Chorionic Gonadotropin Market By Technology, 2020-2030, USD (Million)
- TABLE 27 China Human Chorionic Gonadotropin Market By Treatment, 2020-2030, USD (Million)
- TABLE 28 China Human Chorionic Gonadotropin Market By Technology, 2020-2030, USD (Million)
- TABLE 29 Japan Human Chorionic Gonadotropin Market By Treatment, 2020-2030, USD (Million)
- TABLE 30 Japan Human Chorionic Gonadotropin Market By Technology, 2020-2030, USD (Million)
- TABLE 31 India Human Chorionic Gonadotropin Market By Treatment, 2020-2030, USD (Million)
- TABLE 32 India Human Chorionic Gonadotropin Market By Technology, 2020-2030, USD (Million)
- TABLE 33 Australia Human Chorionic Gonadotropin Market By Treatment, 2020-2030, USD (Million)
- TABLE 34 Australia Human Chorionic Gonadotropin Market By Technology, 2020-2030, USD (Million)
- TABLE 35 South Korea Human Chorionic Gonadotropin Market By Treatment, 2020-2030, USD (Million)
- TABLE 36 South Korea Human Chorionic Gonadotropin Market By Technology, 2020-2030, USD (Million)
- TABLE 37 Latin America Human Chorionic Gonadotropin Market By Treatment, 2020-2030, USD (Million)
- TABLE 38 Latin America Human Chorionic Gonadotropin Market By Technology, 2020-2030, USD (Million)
- TABLE 39 Brazil Human Chorionic Gonadotropin Market By Treatment, 2020-2030, USD (Million)
- TABLE 40 Brazil Human Chorionic Gonadotropin Market By Technology, 2020-2030, USD (Million)
- TABLE 41 Mexico Human Chorionic Gonadotropin Market By Treatment, 2020-2030, USD (Million)
- TABLE 42 Mexico Human Chorionic Gonadotropin Market By Technology, 2020-2030, USD (Million)
- TABLE 43 Rest of Latin America Human Chorionic Gonadotropin Market By Treatment, 2020-2030, USD (Million)
- TABLE 44 Rest of Latin America Human Chorionic Gonadotropin Market By Technology, 2020-2030, USD (Million)
- TABLE 45 Middle East and Africa Human Chorionic Gonadotropin Market By Treatment, 2020-2030, USD (Million)
- TABLE 46 Middle East and Africa Human Chorionic Gonadotropin Market By Technology, 2020-2030, USD (Million)
- TABLE 47 GCC Human Chorionic Gonadotropin Market By Treatment, 2020-2030, USD (Million)
- TABLE 48 GCC Human Chorionic Gonadotropin Market By Technology, 2020-2030, USD (Million)
- TABLE 49 Africa Human Chorionic Gonadotropin Market By Treatment, 2020-2030, USD (Million)
- TABLE 50 Africa Human Chorionic Gonadotropin Market By Technology, 2020-2030, USD (Million)
- TABLE 51 Rest of Middle East and Africa Human Chorionic Gonadotropin Market By Treatment, 2020-2030, USD (Million)
- TABLE 52 Rest of Middle East and Africa Human Chorionic Gonadotropin Market By Technology, 2020-2030, USD (Million)
List of Figures
- FIG. 1 Global Human Chorionic Gonadotropin Market: Market Coverage
- FIG. 2 Research Methodology and Data Sources
- FIG. 3 Market Size Estimation - Top Down & Bottom-Up Approach
- FIG. 4 Global Human Chorionic Gonadotropin Market: Quality Assurance
- FIG. 5 Global Human Chorionic Gonadotropin Market, By Treatment, 2021
- FIG. 6 Global Human Chorionic Gonadotropin Market, By Technology, 2021
- FIG. 7 Global Human Chorionic Gonadotropin Market, By Geography, 2021
- FIG. 8 Market Geographical Opportunity Matrix - Global Human Chorionic Gonadotropin Market, 2021
- FIG. 9 Market Positioning of Key Human Chorionic Gonadotropin Market Players, 2021
- FIG. 10 Global Human Chorionic Gonadotropin Market - Tier Analysis - Percentage of Revenues by Tier Level, 2021 Versus 2030
- FIG. 11 Global Human Chorionic Gonadotropin Market, By Treatment, 2021 Vs 2030, %
- FIG. 12 Global Human Chorionic Gonadotropin Market, By Technology, 2021 Vs 2030, %
- FIG. 13 U.S. Human Chorionic Gonadotropin Market (US$ Million), 2020 - 2030
- FIG. 14 Canada Human Chorionic Gonadotropin Market (US$ Million), 2020 - 2030
- FIG. 15 Rest of North America Human Chorionic Gonadotropin Market (US$ Million), 2020 - 2030
- FIG. 16 UK Human Chorionic Gonadotropin Market (US$ Million), 2020 - 2030
- FIG. 17 Germany Human Chorionic Gonadotropin Market (US$ Million), 2020 - 2030
- FIG. 18 Spain Human Chorionic Gonadotropin Market (US$ Million), 2020 - 2030
- FIG. 19 Italy Human Chorionic Gonadotropin Market (US$ Million), 2020 - 2030
- FIG. 20 France Human Chorionic Gonadotropin Market (US$ Million), 2020 - 2030
- FIG. 21 Rest of Europe Human Chorionic Gonadotropin Market (US$ Million), 2020 - 2030
- FIG. 22 China Human Chorionic Gonadotropin Market (US$ Million), 2020 - 2030
- FIG. 23 Japan Human Chorionic Gonadotropin Market (US$ Million), 2020 - 2030
- FIG. 24 India Human Chorionic Gonadotropin Market (US$ Million), 2020 - 2030
- FIG. 25 Australia Human Chorionic Gonadotropin Market (US$ Million), 2020 - 2030
- FIG. 26 South Korea Human Chorionic Gonadotropin Market (US$ Million), 2020 - 2030
- FIG. 27 Rest of Asia Human Chorionic Gonadotropin Market (US$ Million), 2020 - 2030
- FIG. 28 Brazil Human Chorionic Gonadotropin Market (US$ Million), 2020 - 2030
- FIG. 29 Mexico Human Chorionic Gonadotropin Market (US$ Million), 2020 - 2030
- FIG. 30 Rest of Latin America Human Chorionic Gonadotropin Market (US$ Million), 2020 - 2030
- FIG. 31 GCC Human Chorionic Gonadotropin Market (US$ Million), 2020 - 2030
- FIG. 32 Africa Human Chorionic Gonadotropin Market (US$ Million), 2020 - 2030
- FIG. 33 Rest of Middle East and Africa Human Chorionic Gonadotropin Market (US$ Million), 2020 - 2030
